Abstract
Purpose :
Kahook Dual Blade, Streamline Surgical System, and OMNI Surgical System are popular minimally invasive procedures known for their ability to significantly reduce intraocular pressure (IOP) by promoting aqueous outflow through Schlemm’s canal. Our aim was to compare the efficacy of these procedures combined with phacoemulsification in patients diagnosed with primary open angle glaucoma (POAG) 1-month postoperative as indicated by IOP.
Methods :
This was a retrospective review of 101 eyes diagnosed with POAG that were treated with Kahook (n=45), Streamline (n=27), and OMNI (n=29) and combined phacoemulsification between 2017 and 2023. Statistical analysis involved ANOVA, Tukey’s Honest Significant Difference Test, and paired sample t-tests.
Results :
Baseline IOP (Kahook, 16.2 mmHg; Streamline, 18.3mmHg; OMNI, 16.7mmHg) and number of glaucoma medications (Kahook, 1.5; Streamline, 1.4; OMNI, 1.1) were established. At 1 month, all procedures yielded a statistically significant reduction in IOP (Kahook: -15%, p<0.001; Streamline: -35%, p<0.001; OMNI: -33%, p<0.001). The change in medication burden (Kahook: -119%, p<0.001; Streamline: -71%, p<0.001; OMNI: -91%, p<0.001) was also determined. ANOVA test yielded significant differences between the two groups (p=0.02). Post-hoc Tukey test indicated a significant difference in IOP reduction favoring the Streamline Surgical System versus Kahook Dual Blade (p=0.02). No vision-threatening complications were observed in any group.
Conclusions :
All assessed procedures appeared safe and effective with significant reductions in IOP and medications. Streamline Surgical System may be more favorable in 1-month postoperative IOP reduction compared to Kahook Dual Blade.However, no significant differences in 1-month outcomes between OMNI Surgical System versus Kahook Dual Blade and OMNI Surgical System versus Streamline Surgical System.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.